US · BCRX
BioCryst Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Durham, NC 27703
- Website
- biocryst.com
Price · as of 2025-12-31
$9.19
Market cap 1.84B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $95.65 | +940.81% |
| Intrinsic Value(DCF) | $12,556.39 | +136,531.01% |
| Graham-Dodd Method(GD) | $5.72 | -37.78% |
| Graham Formula(GF) | $123.49 | +1,243.78% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $5.59 | $29.28 | $0.00 | $0.00 | $73.00 |
| 2012 | $1.27 | $27.72 | $0.00 | $0.00 | $0.00 |
| 2013 | $11.46 | $34.49 | $0.00 | $0.00 | $13.30 |
| 2014 | $10.03 | $28.46 | $0.00 | $0.00 | $8.35 |
| 2015 | $2.83 | $52.26 | $19.79 | $0.00 | $0.00 |
| 2016 | $8.88 | $25.75 | $0.00 | $0.00 | $26.41 |
| 2017 | $5.58 | $28.25 | $0.00 | $0.00 | $0.00 |
| 2018 | $7.96 | $25.74 | $0.00 | $0.00 | $8.92 |
| 2019 | $4.11 | $39.55 | $796.74 | $0.00 | $0.00 |
| 2020 | $12.64 | $32.46 | $0.00 | $0.00 | $57.60 |
| 2021 | $16.12 | $113.28 | $1,997.71 | $0.00 | $0.00 |
| 2022 | $8.29 | $34.55 | $1,104.21 | $0.00 | $0.00 |
| 2023 | $5.43 | $28.80 | $601.96 | $0.00 | $0.00 |
| 2024 | $7.69 | $33.03 | $103.11 | $0.00 | $0.00 |
| 2025 | $8.63 | $95.65 | $1,188.79 | $5.72 | $123.49 |
AI valuation
Our deep-learning model estimates BioCryst Pharmaceuticals, Inc.'s (BCRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $95.65
- Current price
- $9.19
- AI upside
- +940.81%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$12,556.39
+136,531.01% upside
Graham-Dodd
$5.72
-37.78% upside
Graham Formula
$123.49
+1,243.78% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BCRX | BioCryst Pharmaceuticals,… | $9.19 | 1.84B | +941% | +136,531% | -38% | +1,244% | 6.86 | -15.20 | 2.07 | 4.45 | — | -15.20 | 97.82% | 38.98% | 30.16% | -88.68% | -199.20% | 52.53% | -0.10 | 4.32 | 2.06 | 1.40 | -0.22 | -38140.00% | 9410.00% | -75364.00% | 19.18% | 1.77 | -205.64% | 0.00% | 0.00% | 44.97% | 4.54 | 4.46 | 1.77 | 1.99 |
| ARDX | Ardelyx, Inc. | $6.55 | 1.59B | +365% | +11,362% | — | — | -25.32 | 9.34 | 3.83 | -51.64 | -47.82 | 9.34 | 90.29% | -10.06% | -15.12% | -36.21% | -43.02% | -13.14% | 1.27 | -1.44 | 4.31 | 3.80 | -4.92 | 5294.00% | 2209.00% | -403.00% | -2.82% | -0.48 | -46.17% | 0.00% | 0.00% | 0.00% | -36.76 | -34.26 | 3.70 | 1.40 |
| MAZE | Maze Therapeutics, Inc. | $45.59 | 2.19B | — | -84% | -77% | — | 10.06 | 2.67 | 3.14 | 5.84 | — | 2.67 | 100.00% | 34.38% | 31.18% | 50.47% | 196.80% | 33.48% | 0.14 | — | 9.76 | 9.52 | -2.80 | -10339.00% | — | -18572.00% | 14.23% | 3.67 | 261.38% | 0.00% | 0.00% | 36.28% | 6.17 | 4.75 | 2.12 | 7.53 |
| NTLA | Intellia Therapeutics, In… | $13.78 | 1.6B | +45% | -49% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| PHVS | Pharvaris N.V. | $28.39 | 1.84B | — | — | — | — | -5.23 | 2.59 | — | -2.84 | — | 2.59 | 0.00% | — | — | -40.62% | 1529.52% | -38.37% | 0.00 | — | 12.60 | 12.35 | 1.92 | -570.00% | — | 2956.00% | -17.42% | -5.23 | 1266.85% | 0.00% | 0.00% | 0.00% | -2.83 | -3.42 | — | 15.12 |
| STOK | Stoke Therapeutics, Inc. | $36.41 | 2.08B | +35% | +5,275% | — | — | -4.86 | 1.89 | 11.83 | -2.20 | — | 1.89 | 100.00% | -277.31% | -243.42% | -45.80% | 800.63% | -35.60% | 0.01 | — | 5.81 | 5.43 | 1.27 | -3067.00% | 31634.00% | 529.00% | -20.12% | -2.17 | 687.55% | 0.00% | 0.00% | 0.00% | -2.15 | -2.50 | 5.96 | 3.33 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| TRVI | Trevi Therapeutics, Inc. | $11.92 | 1.53B | — | — | — | — | -9.07 | 4.36 | — | -6.86 | -14.61 | 4.36 | 0.00% | — | — | -52.59% | 1707.29% | -47.84% | 0.01 | -12881.00 | 10.41 | 10.29 | 0.69 | 6207.00% | — | 2023.00% | -8.81% | -3.64 | 1269.60% | 0.00% | 0.00% | 0.46% | -6.36 | -8.56 | — | 19.07 |
| UPB | Upstream Bio, Inc. | $7.68 | 415.02M | +226% | +2% | -60% | — | -7.31 | 0.98 | 193.67 | 0.12 | -17.44 | 0.98 | 100.00% | -3281.18% | -2650.04% | -36.23% | 67.14% | -20.97% | 0.00 | — | 44.63 | 43.93 | 4.17 | 4190.00% | -42.00% | 5677.00% | -13.00% | -5.51 | 51.53% | 0.00% | 0.00% | 64.98% | 0.12 | 0.16 | -4.06 | 23.29 |
| WVE | Wave Life Sciences Ltd. | $13.93 | 2.59B | +134% | -54% | — | +334% | -11.43 | 4.51 | 54.67 | -8.57 | -15.69 | 4.51 | 0.00% | -504.09% | -478.33% | -56.16% | 323.63% | -108.74% | 0.03 | — | 6.47 | 6.35 | 2.86 | 7286.00% | -6055.00% | 2338.00% | -8.03% | -1.97 | 281.72% | 0.00% | 0.00% | 13.17% | -8.13 | -9.34 | 40.99 | 1.20 |
| ZYME | Zymeworks Inc. | $23.29 | 1.74B | +9% | -79% | — | — | -7.42 | 2.69 | 11.93 | -6.47 | — | 2.83 | 100.00% | -179.69% | -160.80% | -30.54% | -110.26% | -23.51% | 0.05 | — | 3.40 | 3.19 | 0.44 | -581.00% | 38.00% | -757.00% | -12.43% | -1.25 | -90.96% | 0.00% | 0.00% | 3.30% | -5.13 | -6.21 | 9.21 | 1.62 |
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
- CEO
- Charles K. Gayer
- Employees
- 580
- Beta
- 0.79
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($12,556.39 ÷ $9.19) − 1 = +136,531.01% (DCF, example).